Communiqués Cullinan Therapeutics, Inc.

Actions

CGEM

US2300311063

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 12/06/2024			Varia. 5j.	Varia. 1 janv.
21,71 ^USD	-6,62 %		-4,95 %	+113,05 %

02/06	Transcript : Cullinan Therapeutics, Inc. - Special Call
01/06	Cullinan Therapeutics, Inc. annonce les premiers résultats positifs de l'étude pivot de phase 2b Rezil1 sur le Zipalertinib	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib	01/06	AQ
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib	01/06	GL
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit	24/05	GL
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024	23/05	GL
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	15/05	GL
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer	29/04	GL
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer	29/04	AQ
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024	24/04	GL
Cullinan Oncology : Therapeutics Corporate Update	16/04	PU
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases	16/04	GL
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases	16/04	AQ
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement	16/04	GL
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	14/03	GL
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma	01/03	GL
Cullinan Oncology to Participate in Upcoming Investor Conferences	27/02	GL
Cullinan Oncology to Participate in Upcoming Investor Conferences	27/02	AQ
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	18/12	GL
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines	14/12	GL
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines	14/12	AQ
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results	08/11	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cullinan Therapeutics, Inc.

Actions

CGEM

US2300311063

Communiqués

Filtres